Berlin, Germany

Phoebe Markovic

This inventor holds 1 USPTO granted patent. Top assignee: Max-Delbruck-Centrum Fur Molekulare Medizin. Active years: 2014.


Average Co-Inventor Count = 8.0

ph-index = 1


Company Filing History:


Years Active: 2014

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Phoebe Markovic: Innovator in Neurodegenerative Disease Treatment

Introduction

Phoebe Markovic is a prominent inventor based in Berlin, Germany. She has made significant contributions to the field of pharmaceuticals, particularly in the treatment and diagnosis of neurodegenerative diseases. Her innovative work has the potential to impact many lives affected by these conditions.

Latest Patents

Phoebe Markovic holds a patent for "Pharmaceutical and diagnostic compositions for use in the treatment and diagnosis of neurodegenerative diseases or amyloid diseases." This invention relates to pharmaceutical and diagnostic compositions, as well as the use of the active substances contained therein for preparing a pharmaceutical or diagnostic composition for the treatment or diagnosis of neurodegenerative disorders or amyloid diseases. She has 1 patent to her name.

Career Highlights

Markovic is currently affiliated with the Max Delbrück Center for Molecular Medicine, where she conducts her research. Her work focuses on developing innovative solutions to combat neurodegenerative diseases, showcasing her dedication to advancing medical science.

Collaborations

Throughout her career, Phoebe has collaborated with notable colleagues, including Erich Wanker and Annett Boeddrich. These partnerships have enriched her research and contributed to the success of her projects.

Conclusion

Phoebe Markovic is a trailblazer in the field of pharmaceuticals, particularly in addressing neurodegenerative diseases. Her innovative patent and collaborative efforts highlight her commitment to improving healthcare outcomes.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to [email protected]
Loading…